Literature DB >> 19267777

Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.

Sung-In Park1, Claudia R Felipe, Paula G Pinheiro-Machado, Riberto Garcia, Fernanda B Fernandes, Dulce E Casarini, Helio Tedesco-Silva, Jose O Medina-Pestana.   

Abstract

This study was conducted to evaluate time-dependent pharmacokinetic changes and drug interactions over the first 6 months after transplantation in kidney transplant recipients receiving tacrolimus (TAC), prednisone (PRED) and mycophenolate mofetil (MMF) or sirolimus (SRL). Pharmacokinetic assessments were carried out at day 7 and months 1, 3, and 6 in kidney transplant recipients receiving TAC plus PRED with either MMF (2 g/day, n = 13) or SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day, n = 12). There were no differences in the main demographic characteristics or in mean PRED doses during the first 6 months after transplant. From day 7 to month 6, there was a 65% increase in TAC dose corrected exposure (dose corrected area under the curve; AUC) in patients receiving MMF (P = 0.005) and a 59% increase in TAC dose corrected exposure in patients receiving SRL (P = 0.008). From day 7 to month 6, there was a 72% increase in mycophenolate dose corrected exposure (P = 0.001) and a 65% increase in SRL dose corrected exposure (P = 0.008). TAC dose corrected exposure was 23% lower in patients receiving SRL compared with MMF (P = 0.012) on average over the study period. PRED dose reduction was associated with increase in TAC (in patients receiving SRL, P = 0.040) and mycophenolic acid (MPA) (P = 0.070) drug exposures. Tercile distribution of TAC drug exposure showed a positive correlation with mean SRL exposures (P = 0.016). Conversely, tercile distribution of SRL drug exposure showed a positive correlation with mean TAC exposures (P = 0.004). Time-dependent increases in TAC, MPA and SRL drug exposures occur up to 6 months after transplantation. Drug-to-drug interactions indicate that intense therapeutic drug monitoring is required to avoid under- or over-immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267777     DOI: 10.1111/j.1472-8206.2008.00644.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Authors:  Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

2.  The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.

Authors:  Michael A Tortorici; Virginia Parks; Kyle Matschke; Joan Korth-Bradley; Alain Patat
Journal:  Eur J Clin Pharmacol       Date:  2012-10-04       Impact factor: 2.953

3.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

5.  CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.

Authors:  Paola Krall; Dominique Yañez; Angélica Rojo; Ángela Delucchi; Miguel Córdova; Jorge Morales; Pía Boza; Alonso de la Rivera; Natalie Espinoza; Natalia Armijo; Luis E Castañeda; Mauricio J Farfán; Carolina Salas
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

6.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Lorraine A Hamiwka; Vincent Ws Lee; Jeremy R Chapman; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2019-12-16

7.  Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.

Authors:  Leon Louis Seifert; Hauke Heinzow; Iyad Kabar; Stefan Christensen; Anna Hüsing; Hartmut H-J Schmidt
Journal:  Am J Case Rep       Date:  2016-08-24

8.  Effects of cyclophosphamide combined with prednisone on TNF-α expression in treatment of patients with interstitial lung disease.

Authors:  Jun Li; Xiuling Chen; Yunping Qu
Journal:  Exp Ther Med       Date:  2019-10-14       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.